12.2021

APIM Therapeutics announced today that a Phase II Investigator Initiated Study (IIS) of ATX-101 will begin enrolling patients with sarcoma at Columbia University Irving Medical Center. The clinical study will investigate ATX-101 as single agent therapy for patients with leiomyosarcoma and liposarcoma who have received at least one prior treatment. For a copy of the corresponding press release, please follow this link.